Olutasidenib for IDH1-mutated blood disorders
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a condition called CCUS (low blood counts with no clear cause) or low-risk MDS/CMML (a type of blood cancer).
- A blood test shows you have an IDH1 mutation with at least 2 out of every 100 cells affected.
- You are 18 years or older.
- Your liver and kidneys work well enough (blood tests will check this).
- You can take pills by mouth and do not have a serious infection or other uncontrolled medical issue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
This trial combines three drugs—decitabine, venetoclax, and a targeted therapy (olutasidenib)—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It may also be an option for people newly diagnosed with AML who cannot receive intense chemotherapy.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.